RT Journal Article
SR Electronic
A1 Rizzo, Toni
T1 DECIDE: Significantly Improved Brain MRI Results with DAC HYP versus Interferon in RRMS
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 29
SP 6
OP 7
DO 10.1177/155989771429002
UL http://mdc.sagepub.com/content/14/29/6.abstract
AB Daclizumab high-yield process (DAC HYP) is a humanized monoclonal antibody specific for CD25, the alpha subunit of the interleukin 2 receptor [Gold R et al. Lancet. 2013]. This article presents the magnetic resonance imaging (MRI) data from the phase 3 Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β1a in Patients With Relapsing-Remitting Multiple Sclerosis trial [DECIDE; NCT01064401].